Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 25Recurrence 3Smoldering Multiple Myeloma 2Neuroblastoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Ganglioneuroblastoma 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 7dinutuximab 6Topotecan 5Isotretinoin 5Doxorubicin 5Biopsy 5sargramostim 4Vincristine 4Stem Cell Transplantation 4Specimen Handling 4Radiation 4Platinum 4Melphalan 4Colony-Stimulating Factors 4Cisplatin 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4Thiotepa 3Temozolomide 3Irinotecan 3Etoposide 3Congresses as Topic 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2Busulfan 2lorlatinib 1iberdomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × iberdomide × 1 year × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡